▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for IVERIC bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.84.
The current consensus among 0 contributing investment analysts is to n/a stock in IVERIC bio. This rating has held steady since July 2019, when it changed from a Hold consensus rating.
IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.